{
    "clinical_study": {
        "@rank": "112611", 
        "acronym": "SIL-REACT", 
        "arm_group": {
            "arm_group_label": "Sildenafil", 
            "arm_group_type": "Experimental", 
            "description": "oral Sildenafil 20 mg three times a day for 90 days"
        }, 
        "brief_summary": {
            "textblock": "Sildenafil is a selective pulmonary vasodilator; in patients with a special kind of\n      pulmonary hypertension it is approved for treatment. The trial seeks to find out, whether\n      the acute response to this treatment (= vasoreactivity testing) given intravenously is\n      effective and allows prediction of therapy success during a following oral treatment."
        }, 
        "brief_title": "VasoREACTivity Testing With Intravenous SILdenafil in Patients With Precapillary Pulmonary Hypertension", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Pulmonary Hypertension Associated With Connective Tissue Disease", 
        "condition_browse": {
            "mesh_term": [
                "Connective Tissue Diseases", 
                "Hypertension", 
                "Hypertension, Pulmonary"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Precapillary pulmonary hypertension associated with connective tissue disease\n\n          -  resting mean pressure in the pulmonary artery of > 24 mmHg\n\n          -  resting mean pulmonary capillary wedge pressure (PCWP) of < 16 mmHg\n\n          -  age 18 to 80 years\n\n          -  women of childbearing potential must have a negative pregnancy test (\u00df-HCG in urine)\n             and must use   effective methods of contraception\n\n          -  women must not be breastfeeding\n\n          -  ability to understand and sign the informed consent, correctly signed informed\n             consent\n\n        Exclusion Criteria:\n\n          -  pretreatment with Sildenafil\n\n          -  contraindications for Sildenafil treatment:\n\n               -  known intolerance to Sildenafil,\n\n               -  optic neuropathy (NAION),\n\n               -  known hereditary retina disease,\n\n               -  need of nitrate therapy\n\n          -  advanced liver cirrhosis - CHILD C\n\n          -  severely reduced renal function with GFR < 30 ml/min/1,73 m\u00b2\n\n          -  stroke or myocardial infarction within the last 6 months"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01889966", 
            "org_study_id": "WS2196851"
        }, 
        "intervention": {
            "arm_group_label": "Sildenafil", 
            "description": "oral Sildenafil 3 x 20 mg for 90 days", 
            "intervention_name": "Sildenafil", 
            "intervention_type": "Drug", 
            "other_name": [
                "Revatio", 
                "CAS15 number 139755-83-2", 
                "EV Substance code SUB10517MIG"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Sildenafil"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "vasoreactivity testing", 
            "Sildenafil", 
            "precapillary pulmonary hypertension", 
            "connective tissue disease", 
            "mean pressure in the pulmonary artery 25 mmHg or more", 
            "mean pulmonary capillary wedge pressure below 16 mmHg"
        ], 
        "lastchanged_date": "June 26, 2013", 
        "location": {
            "contact": {
                "email": "a.rieth@kerckhoff-klinik.de", 
                "last_name": "Andreas J Rieth, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Bad Nauheim", 
                    "country": "Germany", 
                    "zip": "61231"
                }, 
                "name": "Kerckhoff Heart Center"
            }, 
            "investigator": [
                {
                    "last_name": "Andreas J Rieth, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Veselin Mitrovic, MD Prof.", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "1", 
        "official_title": "Vasoreactivity Testing With Intravenous Sildenafil in Patients With Precapillary Pulmonary Hypertension (Treatment Optimisation Study)", 
        "overall_contact": {
            "email": "a.rieth@kerckhoff-klinik.de", 
            "last_name": "Andreas J Rieth, MD", 
            "phone": "+49 (0) 60329962677"
        }, 
        "overall_contact_backup": {
            "email": "C.Reuschling@kerckhoff-forschungs-gmbh.de", 
            "last_name": "Christina Reuschling", 
            "phone": "+49 (0) 60329962252"
        }, 
        "overall_official": {
            "affiliation": "Kerckhoff Heart Center", 
            "last_name": "Andreas J Rieth, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Right heart catheterisation with comprehensive hemodynamic measurements (pressures in RA, RV, PA, PCW position; cardiac index (CI) by thermodilution; oxygen saturation in the PA; the same under exercise conditions) is performed. In case of precapillary pulmonary hypertension, Sildenafil is given I.V. and acute tolerability, safety and efficacy on hemodynamic parameters are registrated. Successful vasoreactivity testing is defined by lowering the mean PA pressure by 10 mmHg or more, lowering it below 40 mmHg and maintaining / rising of the CI. Safety is mainly defined by lack of a substantial effect of the study drug on systemic blood pressure.", 
            "measure": "efficacy of Sildenafil I.V. for vasoreactivity testing", 
            "safety_issue": "Yes", 
            "time_frame": "1.5 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01889966"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Kerckhoff Heart Center", 
            "investigator_full_name": "Dr. Andreas Rieth", 
            "investigator_title": "Dr. med., senior physician cardiology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Complete hemodynamic and functional assessment after 90 days of oral Sildenafil therapy (same protocol as before except vasoreactivity testing). Hemodynamic parameters which characterize successful oral therapy are mainly mean PA-pressure (decrease), pulmonary vascular resistance (decrease) and cardiac index (increase) - at rest and exercise.\nFunctional improvement is further characterized by exercise capacity (cardiopulmonary exercise testing: improvement of V\u00b4O2 peak by \u2265 1 ml/min/kg), fall of NTproBNP, improvement of echocardiographic parameters of right ventricular function (TAPSE, S\u00b4, RV-FAC).\nEvaluation, if positive initial vasoreactivity testing results in successful oral therapy as defined above.", 
            "measure": "clinical efficacy of sildenafil per os predicted by testing it intravenously in the course of oral therapy", 
            "safety_issue": "No", 
            "time_frame": "90 days"
        }, 
        "source": "Kerckhoff Heart Center", 
        "sponsors": {
            "collaborator": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Kerckhoff Heart Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}